L ALANOSINE THERAPY FOR MTAP DEFICIENT LUNG CANCER

l丙氨酸疗法用于MTAP缺乏肺癌

• 批准号: 6118004
• 负责人: CARLOS J CARRERA
• 金额: $ 1.46万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6118004
• 关键词: adenine nucleotides; antineoplastic antibiotics; biosynthesis; clinical research; cyclic AMP; human subject; human therapy evaluation; lung neoplasms; neoplasm /cancer chemotherapy

Design a selective chemotherapeutic strategy for approximately 30% of non-small cell lung cancers that are MTAP-deficient using the anti-tumor L-alanosine as a potent inhibitor of de novo AMP synthesis. Determine if tumors lacking the ability to salvage MTAP are more sensitive to inhibition of de novo adenine nucleotide synthesis than normal tissue and determine if unique antibiotic L-alanosine can cause selective depletion of adenine nucleotides in MTAP-deficient tumors.

设计一种选择性化疗策略，使用抗肿瘤的l -丙氨酸作为从头合成AMP的有效抑制剂，治疗大约30%的mtap缺乏的非小细胞肺癌。确定缺乏挽救MTAP能力的肿瘤是否比正常组织对新生腺嘌呤核苷酸合成的抑制更敏感，并确定在MTAP缺乏的肿瘤中，独特的抗生素l -丙氨酸是否会导致腺嘌呤核苷酸的选择性消耗。